![](/img/cover-not-exists.png)
665TiPSOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
Andre, T, Saunders, M P, Kanehisa, A, Gandossi, E, Fougeray, R, Causse-Amellal, N, Falcone, AVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz246.142
Date:
October, 2019
File:
PDF, 82 KB
2019